Nautilus Biotechnology Net Income
| NAUT Stock | USD 2.19 0.06 2.82% |
As of the 14th of February 2026, Nautilus Biotechnology secures the Risk Adjusted Performance of 0.0907, downside deviation of 5.09, and Mean Deviation of 4.17. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Nautilus Biotechnology, as well as the relationship between them.
Analyzing historical trends in various income statement and balance sheet accounts from Nautilus Biotechnology's financial statements helps investors evaluate the company's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Nautilus Biotechnology's valuation are summarized below:There are currently one hundred twenty fundamental ratios for Nautilus Biotechnology that can be evaluated and compared over time across peers in the industry. All traders should check Nautilus Biotechnology's last-minute fundamentals against the performance from 2010 to 2026 and make sure the trends continue to evolve in the right direction. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. | Last Reported | Projected for Next Year | ||
| Net Loss | -63.7 M | -60.5 M | |
| Net Loss | -52.1 M | -54.7 M | |
| Net Loss | -63.7 M | -66.9 M | |
| Net Loss | (0.65) | (0.62) |
Nautilus | Net Income | Build AI portfolio with Nautilus Stock |
The evolution of Net Income for Nautilus Biotechnology provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Nautilus Biotechnology compares to historical norms and industry peers.
Latest Nautilus Biotechnology's Net Income Growth Pattern
Below is the plot of the Net Income of Nautilus Biotechnology over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Nautilus Biotechnology financial statement analysis. It represents the amount of money remaining after all of Nautilus Biotechnology operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Nautilus Biotechnology's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Nautilus Biotechnology's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (70.78 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Nautilus Net Income Regression Statistics
| Arithmetic Mean | 308,661,771 | |
| Geometric Mean | 173,171,914 | |
| Coefficient Of Variation | 112.73 | |
| Mean Deviation | 336,640,478 | |
| Median | 626,600,000 | |
| Standard Deviation | 347,943,093 | |
| Sample Variance | 121064.4T | |
| Range | 697.4M | |
| R-Value | (0.88) | |
| Mean Square Error | 29816.8T | |
| R-Squared | 0.77 | |
| Slope | (60,426,964) | |
| Total Sum of Squares | 1937030.3T |
Nautilus Net Income History
Other Fundumenentals of Nautilus Biotechnology
| Net Income Applicable To Common Shares | ||
| Net Income From Continuing Ops | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Nautilus Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Nautilus Biotechnology is extremely important. It helps to project a fair market value of Nautilus Stock properly, considering its historical fundamentals such as Net Income. Since Nautilus Biotechnology's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Nautilus Biotechnology's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Nautilus Biotechnology's interrelated accounts and indicators.
Click cells to compare fundamentals
Is there potential for Biotechnology market expansion? Will Nautilus introduce new products? Factors like these will boost the valuation of Nautilus Biotechnology. Anticipated expansion of Nautilus directly elevates investor willingness to pay premium valuations. Understanding fair value requires weighing current performance against future potential. All the valuation information about Nautilus Biotechnology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Nautilus Biotechnology's market price often diverges from its book value, the accounting figure shown on Nautilus's balance sheet. Smart investors calculate Nautilus Biotechnology's intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Since Nautilus Biotechnology's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
It's important to distinguish between Nautilus Biotechnology's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Nautilus Biotechnology should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. However, Nautilus Biotechnology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Nautilus Biotechnology 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Nautilus Biotechnology's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Nautilus Biotechnology.
| 11/16/2025 |
| 02/14/2026 |
If you would invest 0.00 in Nautilus Biotechnology on November 16, 2025 and sell it all today you would earn a total of 0.00 from holding Nautilus Biotechnology or generate 0.0% return on investment in Nautilus Biotechnology over 90 days. Nautilus Biotechnology is related to or competes with Foghorn Therapeutics, Immuneering Corp, Enanta Pharmaceuticals, Pyxis Oncology, Tenaya Therapeutics, Zura Bio, and Assembly Biosciences. Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for q... More
Nautilus Biotechnology Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Nautilus Biotechnology's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Nautilus Biotechnology upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 5.09 | |||
| Information Ratio | 0.0894 | |||
| Maximum Drawdown | 28.35 | |||
| Value At Risk | (7.62) | |||
| Potential Upside | 9.29 |
Nautilus Biotechnology Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Nautilus Biotechnology's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Nautilus Biotechnology's standard deviation. In reality, there are many statistical measures that can use Nautilus Biotechnology historical prices to predict the future Nautilus Biotechnology's volatility.| Risk Adjusted Performance | 0.0907 | |||
| Jensen Alpha | 0.5861 | |||
| Total Risk Alpha | 0.1453 | |||
| Sortino Ratio | 0.0991 | |||
| Treynor Ratio | (1.54) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Nautilus Biotechnology's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Nautilus Biotechnology February 14, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0907 | |||
| Market Risk Adjusted Performance | (1.53) | |||
| Mean Deviation | 4.17 | |||
| Semi Deviation | 4.32 | |||
| Downside Deviation | 5.09 | |||
| Coefficient Of Variation | 982.01 | |||
| Standard Deviation | 5.64 | |||
| Variance | 31.79 | |||
| Information Ratio | 0.0894 | |||
| Jensen Alpha | 0.5861 | |||
| Total Risk Alpha | 0.1453 | |||
| Sortino Ratio | 0.0991 | |||
| Treynor Ratio | (1.54) | |||
| Maximum Drawdown | 28.35 | |||
| Value At Risk | (7.62) | |||
| Potential Upside | 9.29 | |||
| Downside Variance | 25.9 | |||
| Semi Variance | 18.69 | |||
| Expected Short fall | (5.31) | |||
| Skewness | 0.5421 | |||
| Kurtosis | 1.51 |
Nautilus Biotechnology Backtested Returns
Nautilus Biotechnology appears to be dangerous, given 3 months investment horizon. Nautilus Biotechnology has Sharpe Ratio of 0.0685, which conveys that the firm had a 0.0685 % return per unit of risk over the last 3 months. We have found twenty-eight technical indicators for Nautilus Biotechnology, which you can use to evaluate the volatility of the firm. Please exercise Nautilus Biotechnology's Mean Deviation of 4.17, downside deviation of 5.09, and Risk Adjusted Performance of 0.0907 to check out if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Nautilus Biotechnology holds a performance score of 5. The company secures a Beta (Market Risk) of -0.37, which conveys possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Nautilus Biotechnology are expected to decrease at a much lower rate. During the bear market, Nautilus Biotechnology is likely to outperform the market. Please check Nautilus Biotechnology's sortino ratio, semi variance, as well as the relationship between the Semi Variance and rate of daily change , to make a quick decision on whether Nautilus Biotechnology's current price movements will revert.
Auto-correlation | -0.16 |
Insignificant reverse predictability
Nautilus Biotechnology has insignificant reverse predictability. Overlapping area represents the amount of predictability between Nautilus Biotechnology time series from 16th of November 2025 to 31st of December 2025 and 31st of December 2025 to 14th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Nautilus Biotechnology price movement. The serial correlation of -0.16 indicates that over 16.0% of current Nautilus Biotechnology price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.16 | |
| Spearman Rank Test | -0.27 | |
| Residual Average | 0.0 | |
| Price Variance | 0.01 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Nautilus Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Nautilus Biotechnology reported net income of (70.78 Million). This is 120.74% lower than that of the Biotechnology sector and 201.05% lower than that of the Health Care industry. The net income for all United States stocks is 112.4% higher than that of the company.
Nautilus Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Nautilus Biotechnology's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Nautilus Biotechnology could also be used in its relative valuation, which is a method of valuing Nautilus Biotechnology by comparing valuation metrics of similar companies.Nautilus Biotechnology is currently under evaluation in net income category among its peers.
Nautilus Biotechnology ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Nautilus Biotechnology's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Nautilus Biotechnology's managers, analysts, and investors.Environmental | Governance | Social |
Nautilus Biotechnology Institutional Holders
Institutional Holdings refers to the ownership stake in Nautilus Biotechnology that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Nautilus Biotechnology's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Nautilus Biotechnology's value.| Shares | Renaissance Technologies Corp | 2025-06-30 | 619.9 K | Geode Capital Management, Llc | 2025-06-30 | 553.6 K | Dimensional Fund Advisors, Inc. | 2025-06-30 | 550.7 K | Ci Private Wealth Llc | 2025-06-30 | 435.4 K | Goldman Sachs Group Inc | 2025-06-30 | 314.9 K | Jane Street Group Llc | 2025-06-30 | 290.4 K | Sentinel Trust Co Lba | 2025-06-30 | 280 K | Jacobs Levy Equity Management, Inc. | 2025-06-30 | 254.9 K | Alyeska Investment Group, L.p. | 2025-06-30 | 253.5 K | Perceptive Advisors Llc | 2025-06-30 | 12.6 M | Cercano Management Llc | 2025-06-30 | 7.2 M |
Nautilus Fundamentals
| Return On Equity | -0.32 | ||||
| Return On Asset | -0.19 | ||||
| Current Valuation | 164.61 M | ||||
| Shares Outstanding | 126.31 M | ||||
| Shares Owned By Insiders | 33.50 % | ||||
| Shares Owned By Institutions | 45.90 % | ||||
| Number Of Shares Shorted | 307.31 K | ||||
| Price To Book | 1.59 X | ||||
| EBITDA | (64.43 M) | ||||
| Net Income | (70.78 M) | ||||
| Cash And Equivalents | 299.34 M | ||||
| Cash Per Share | 2.40 X | ||||
| Total Debt | 30.48 M | ||||
| Debt To Equity | 0.09 % | ||||
| Current Ratio | 49.75 X | ||||
| Book Value Per Share | 1.34 X | ||||
| Cash Flow From Operations | (59.15 M) | ||||
| Short Ratio | 1.44 X | ||||
| Earnings Per Share | (0.50) X | ||||
| Target Price | 2.5 | ||||
| Number Of Employees | 124 | ||||
| Beta | 1.36 | ||||
| Market Capitalization | 269.03 M | ||||
| Total Asset | 242.74 M | ||||
| Retained Earnings | (273.02 M) | ||||
| Working Capital | 125.19 M | ||||
| Net Asset | 242.74 M |
About Nautilus Biotechnology Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Nautilus Biotechnology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Nautilus Biotechnology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Nautilus Biotechnology based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Nautilus Stock Analysis
When running Nautilus Biotechnology's price analysis, check to measure Nautilus Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nautilus Biotechnology is operating at the current time. Most of Nautilus Biotechnology's value examination focuses on studying past and present price action to predict the probability of Nautilus Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nautilus Biotechnology's price. Additionally, you may evaluate how the addition of Nautilus Biotechnology to your portfolios can decrease your overall portfolio volatility.